• Publications
  • Influence
Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of docetaxel and paclitaxel in human plasma and oral fluid.
TLDR
A sensitive and robust method was obtained, which fulfilled all validation criteria, and accuracy varied from 91.3 to 103.6%, and imprecision did not exceed 12.7% for all analytes in plasma and oral fluid. Expand
Tobacco and occupation as risk factors in bladder cancer: A case‐control study in southern belgium
TLDR
It seems that the risk of bladder cancer is increased in a log‐linear way by these variables, and an increased risk for metal workers, truck and engine drivers, coal‐miners, and rubber and coal‐tar workers is revealed. Expand
ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian
TLDR
Tranbananib demonstrated anticancer activity in this phase 3 study, indicated by improved ORR and DOR, and Median PFS was not improved. Expand
Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer
TLDR
The authors' data reveal significant correlations between genetic variants of transport, hepatic metabolism, platinum related detoxification or DNA damage repair and toxicity or outcome in ovarian cancer. Expand
Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer.
TLDR
Neoadjuvant XT (HXT in HER2-positive disease) is highly effective in inoperable LABC, demonstrating pCR rates of 15% and 40%, respectively. Expand
Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study
TLDR
Although numbers were too small for statistical significance, pregnancy‐associated physiologic alterations appear to lead to a decrease in plasma exposure of chemotherapeutic drugs. Expand
Clinical Outcome of ET-743 (Trabectedin; Yondelis) in High-Grade Uterine Sarcomas: Report on Five Patients and a Review of the Literature
TLDR
Results on the use of ET-743 in uterine sarcoma patients support the conductance of larger trials and show a clinical benefit in 2/5 patients, which shows support in larger trials. Expand
Iodine-123-interleukin-2 scintigraphy in metastatic hypernephroma: a pilot study.
TLDR
In this small series of patients with MRCC, (123)I-IL-2 uptake was found in tumors of 2 patients who less likely will benefit from cytokine treatment, and additional studies are needed to assess the relationship between the pretreatment uptake of (123)/I- IL2 in MRCC and the response to IL-2 therapy. Expand
Multicenter phase II study of neoadjuvant capecitabine (X), docetaxel (T) ± trastuzumab (H) for patients (pts) with locally advanced breast cancer (LABC): final analysis.
TLDR
Final efficacy data of TX ±H in LABC shows the important contribution of H in achieving pCR, although the different biology of HER2-positive tumors might also account for differences in efficacy. Expand
Adherence to oral anticancer drugs (OAD) in patients (pts) with metastatic renal cancer (mRCC): First results of the prospective observational multicenter IPSOC study (Investigating Patient
TLDR
The aim of this study is to investigate the prevalence and severity of non-adherence to OAD in mRCC and to identify factors predictive of non -adherence. Expand
...
1
2
...